JP7189127B2 - 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 - Google Patents

非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 Download PDF

Info

Publication number
JP7189127B2
JP7189127B2 JP2019512804A JP2019512804A JP7189127B2 JP 7189127 B2 JP7189127 B2 JP 7189127B2 JP 2019512804 A JP2019512804 A JP 2019512804A JP 2019512804 A JP2019512804 A JP 2019512804A JP 7189127 B2 JP7189127 B2 JP 7189127B2
Authority
JP
Japan
Prior art keywords
liver
hoba
nash
liver disease
nafld
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019512804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526598A (ja
Inventor
ラスメイチャー，ジョン
アブムラド，ナジ
フリン，チャールズ
Original Assignee
メタボリック・テクノロジーズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタボリック・テクノロジーズ，インコーポレーテッド filed Critical メタボリック・テクノロジーズ，インコーポレーテッド
Publication of JP2019526598A publication Critical patent/JP2019526598A/ja
Priority to JP2022192727A priority Critical patent/JP2023022236A/ja
Application granted granted Critical
Publication of JP7189127B2 publication Critical patent/JP7189127B2/ja
Priority to JP2024213390A priority patent/JP2025032245A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2019512804A 2016-09-06 2017-09-06 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法 Active JP7189127B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022192727A JP2023022236A (ja) 2016-09-06 2022-12-01 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法
JP2024213390A JP2025032245A (ja) 2016-09-06 2024-12-06 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383895P 2016-09-06 2016-09-06
US62/383,895 2016-09-06
US201662410133P 2016-10-19 2016-10-19
US62/410,133 2016-10-19
PCT/US2017/050317 WO2018048932A1 (en) 2016-09-06 2017-09-06 Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022192727A Division JP2023022236A (ja) 2016-09-06 2022-12-01 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法

Publications (2)

Publication Number Publication Date
JP2019526598A JP2019526598A (ja) 2019-09-19
JP7189127B2 true JP7189127B2 (ja) 2022-12-13

Family

ID=61562136

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512804A Active JP7189127B2 (ja) 2016-09-06 2017-09-06 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法
JP2022192727A Pending JP2023022236A (ja) 2016-09-06 2022-12-01 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法
JP2024213390A Pending JP2025032245A (ja) 2016-09-06 2024-12-06 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022192727A Pending JP2023022236A (ja) 2016-09-06 2022-12-01 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法
JP2024213390A Pending JP2025032245A (ja) 2016-09-06 2024-12-06 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法

Country Status (8)

Country Link
US (3) US20180153827A1 (enExample)
EP (1) EP3510014A4 (enExample)
JP (3) JP7189127B2 (enExample)
CN (2) CN110177771B (enExample)
AU (1) AU2017324935B2 (enExample)
CA (1) CA3035897A1 (enExample)
MX (1) MX2019002579A (enExample)
WO (1) WO2018048932A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532591A (ja) * 2017-09-05 2020-11-12 エムティーアイ・バイオテク，インコーポレーテッド 肝臓の線維症を治療、予防、又は改善するためのγ−ケトアルデヒド捕捉剤の組成物とその使用の方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201074A1 (en) * 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers
EP3914359B1 (en) * 2019-01-25 2025-03-26 MTI Biotech, Inc. Triphenylphosphonium-tethered salicylamine derivatives
CN114344448A (zh) * 2022-01-20 2022-04-15 广西医科大学第一附属医院 Pmx-53多肽在制备治疗非酒精性脂肪性肝炎药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524918A (ja) 2011-07-12 2014-09-25 ヴァンダービルト ユニバーシティー ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023063A2 (en) * 1998-10-22 2000-04-27 University Of South Carolina Methods for inhibiting diabetic complications
CA2369560C (en) * 1999-04-27 2011-02-01 Makoto Nakamuta Agent for prophylaxis and treatment of liver disease
CN1628650A (zh) * 2003-12-19 2005-06-22 刘力 复方二氯醋酸二异丙胺冻干粉针制剂及其制备方法
US8822542B2 (en) * 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
EP2281557A4 (en) 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
US20150087660A1 (en) * 2012-05-10 2015-03-26 Mahesh Kandula Compositions and methods for the treatment of chronic diseases and inflammatory disorders
US20150265584A1 (en) * 2014-03-18 2015-09-24 Vanderbilt University Levuglandin adducts histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with dna
JP2017537149A (ja) * 2014-11-11 2017-12-14 ヴァンダービルト ユニバーシティー 急性腎傷害を制限するための方法
WO2017033119A1 (en) * 2015-08-25 2017-03-02 Rao M Surya Compositions and methods for the treatment of liver metabolic diseases
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
MX2020002441A (es) * 2017-09-05 2020-09-03 Mti Biotech Inc Composiciones y metodos de uso de depuradores de gammacetoaldehido para tratar, prevenir o mejorar fibrosis del higado.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014524918A (ja) 2011-07-12 2014-09-25 ヴァンダービルト ユニバーシティー ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAENS, K.H.J., et al.，Journal of Hepatology，2012年，Vol.56, No.3，pp.647-655.
LONGATO, L. et al.，Hepatology，2014年，Vol.60, No.4(Suppl)，p.579A, Abstract No.785

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532591A (ja) * 2017-09-05 2020-11-12 エムティーアイ・バイオテク，インコーポレーテッド 肝臓の線維症を治療、予防、又は改善するためのγ−ケトアルデヒド捕捉剤の組成物とその使用の方法
JP7441170B2 (ja) 2017-09-05 2024-02-29 エムティーアイ・バイオテク，インコーポレーテッド 肝臓の線維症を治療、予防、又は改善するためのγ－ケトアルデヒド捕捉剤の組成物とその使用の方法

Also Published As

Publication number Publication date
EP3510014A4 (en) 2020-05-20
AU2017324935B2 (en) 2021-10-21
AU2017324935A1 (en) 2019-03-28
MX2019002579A (es) 2020-02-05
CN110177771B (zh) 2022-12-13
CA3035897A1 (en) 2018-03-15
US20180153827A1 (en) 2018-06-07
JP2023022236A (ja) 2023-02-14
US20230181494A1 (en) 2023-06-15
WO2018048932A1 (en) 2018-03-15
JP2019526598A (ja) 2019-09-19
CN110177771A (zh) 2019-08-27
US12383515B2 (en) 2025-08-12
EP3510014A1 (en) 2019-07-17
CN119345198A (zh) 2025-01-24
BR112019004404A2 (pt) 2019-05-28
US20250360094A1 (en) 2025-11-27
JP2025032245A (ja) 2025-03-11

Similar Documents

Publication Publication Date Title
JP2023022236A (ja) 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）、ｎａｓｈ、ａｌｄまたは肝臓に関する状態の治療、予防または改善のためのガンマ－ケトアルデヒドスカベンジャーの組成物および使用方法
Zeng et al. Oleic acid ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of ER stress and pyroptosis
Gomaa et al. Polyphenol-rich Boswellia serrata gum prevents cognitive impairment and insulin resistance of diabetic rats through inhibition of GSK3β activity, oxidative stress and pro-inflammatory cytokines
Impellizzeri et al. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD)
Abdel-Tawab et al. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data
Ota et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis
Niu et al. Protective effect of gentiopicroside against dextran sodium sulfate induced colitis in mice
CN111182904A (zh) 包含acc抑制剂的组合治疗
RS59637B1 (sr) Tretiranje nafld i nash
Sharawy et al. Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation/NF-κB inhibition
Arai et al. Acrolein, a highly toxic aldehyde generated under oxidative stress in vivo, aggravates the mouse liver damage after acetaminophen overdose
KR20060129082A (ko) 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과연관된 질환 또는 질병의 치료 방법
Chen et al. Exogenous hydrogen sulfide ameliorates diabetes-associated cognitive dysfunction by regulating the nrf-2/HO-1 axis and the NLRP3 inflammasome pathway in diabetic rats
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
Griggs et al. Pharmacologic comparison of clinical neutral endopeptidase inhibitors in a rat model of acute secretory diarrhea
HK40012573B (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
HK40012573A (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver
WO2016138132A1 (en) Dipeptidyl peptidase-iv(dpp4) inhibitors, methods and compositions for suppressing adipose tissue inflammation
BR112019004404B1 (pt) Uso de um composto
Oliveira N-Acetylcysteine (nac): impacts on human health
Lee et al. Parapyruvate induces neurodegeneration in C57BL/6JNarl mice via Inhibition of the α-ketoglutarate dehydrogenase complex
JP7441170B2 (ja) 肝臓の線維症を治療、予防、又は改善するためのγ－ケトアルデヒド捕捉剤の組成物とその使用の方法
Tang et al. Liuweizhiji Gegen-Sangshen beverage protects against alcoholic liver disease in mice through the gut microbiota mediated SCFAs/GPR43/GLP-1 pathway
Wang et al. Liuweizhiji Gegen-Sangshen beverage protects against
Zhang et al. Antioxidant and neuroprotective

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221201

R150 Certificate of patent or registration of utility model

Ref document number: 7189127

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250